MAPT and tauopathy: Some authors reported increased in vivo [18F]-AV-1451 retention in patients clinically diagnosed with non-Alzheimer (non-AD) tauopathies in regions that are expected to contain tau lesions while others noticed in vivo binding patterns nearly indistinguishable from those in normal controls [1, 3, 4].